Abstract
Amgen will report its quarterly results on April 30, 2026 Post Market; investors are watching revenue growth, margin resilience after integration costs, and pipeline catalysts that could shape the year’s trajectory.
Market Forecast
Based on current-quarter projections, Amgen’s revenue is expected to be 8.59 billion US dollars, up 6.60% year over year, with EBIT estimated at 3.63 billion US dollars, implying 9.07% YoY growth, and adjusted EPS estimated at 4.76, up 10.79% YoY. Margin forecasts were not disclosed, but the focus remains on sustaining EPS growth as product mix and amortization expenses evolve post-integration of acquired assets.
Amgen’s core business remains its product sales, where the previous quarter’s sales mix was highly concentrated in products. Looking ahead, the company’s most promising growth engines are concentrated within the product bucket; products contributed 9.37 billion US dollars last quarter and, given they comprised about 95% of total revenue, their approximate YoY momentum likely tracked the company’s 8.59% revenue growth, with select therapies such as Repatha and Evenity cited by analysts for outpacing the average.
Last Quarter Review
In the prior quarter, Amgen delivered revenue of 9.87 billion US dollars, a gross profit margin of 72.88%, GAAP net profit attributable to shareholders of 1.33 billion US dollars, a net profit margin of 13.51%, and adjusted EPS of 5.29, which represented a YoY change of -0.38%.
A financial highlight was the maintenance of a high gross margin profile despite the drag from acquisition-related amortization and profit-share expenses that weighed on the cost line in the recent period. On the business mix, products accounted for 9.37 billion US dollars of revenue while other revenues were 499.00 million US dollars; given products comprise roughly 95% of the top line, product growth likely approximated the company-level YoY revenue increase of 8.59%.
Current Quarter Outlook
Main business this quarter: product-driven revenue and margin cadence
Amgen’s near-term revenue remains anchored by product sales, so the quarter will likely be defined by volume trends in chronic therapies and the early impact from recently integrated assets. The forecast points to 8.59 billion US dollars in revenue and 4.76 of adjusted EPS, suggesting that despite seasonal and payer dynamics, the underlying model is set to expand both the top line and per-share earnings year over year. The EBIT estimate of 3.63 billion US dollars reflects operating leverage from higher volumes and cost controls, partially offset by ongoing amortization and royalty burdens tied to acquired franchises.
Margins are the key swing factor within the core product bucket. Last quarter’s 72.88% gross margin and 13.51% net margin frame the baseline, but cost of sales has been elevated by amortization of acquired intangibles and higher profit-share obligations. If unit mix continues to tilt toward faster-growing brands that carry healthier contribution, gross margin should hold near the low-70s even as integration costs persist; however, a heavier mix of co-promoted or royalty-bearing products could keep net margin capped relative to historical peaks. The net effect this quarter will depend on how much price pressure and payer mix offset volume gains in high-growth categories.
On growth, the product portfolio is expected to benefit from continued adoption in cardiometabolic and bone health, while immunology and oncology assets stabilize the base. Analysts have highlighted that select brands like Repatha and Evenity delivered strong growth last year, contributing to confidence that volume expansion can continue to support revenue even as legacy assets face maturational headwinds. In the absence of an explicit margin guide, investors will parse commentary for how price, mix, and amortization trends translate into EBIT and EPS throughput.
Most promising growth driver this quarter: selective brands and integrated assets
The most promising drivers this quarter are clustered around selected brands in cardiovascular and bone health, along with integrated franchises from recent acquisitions and emerging oncology assets. Commentary from analysts indicates that Repatha and Evenity grew between 30% and 50% last year, pointing to continued patient penetration and structural tailwinds in large, underpenetrated markets; sustained prescription trends in these therapies can materially influence quarterly revenue above the overall company growth rate of 6.60% expected for this period. Within the total product bucket, which was 9.37 billion US dollars in the last reported quarter, these growth engines are positioned to carry a disproportionate share of incremental dollars.
On the integrated side, thyroid eye disease therapy developments are in focus. Amgen announced positive phase 3 results for a subcutaneous on-body injector formulation for Tepezza that achieved efficacy comparable to the intravenous version and met its primary and key secondary endpoints. While regulatory and launch timing considerations extend beyond a single quarter, the data trajectory supports a path to broaden the addressable patient base and improve treatment convenience, which could accelerate adoption once commercialized and, over time, lift both revenue and margin contributions.
Oncology is another watchpoint given recent collaborations and product advances. The company’s bispecific T-cell engager strategy is gaining external validation via clinical trial collaborations, and analysts have flagged newly emerging oncology assets as part of a diversified growth framework. Although revenue from these programs may be modest at first, the signaling value for medium-term growth is material; positive updates can support sentiment and multiple resilience, especially when coupled with ongoing strength in core brands.
Stock-price swing factors this quarter: margin dynamics, pipeline updates, and sentiment
The first swing factor is margin translation from revenue to EBIT and EPS. With the quarter expected to produce 3.63 billion US dollars of EBIT and 4.76 in adjusted EPS, investors will focus on the cost-of-goods trajectory given prior commentary that cost of sales rose due to amortization and profit-sharing obligations. Clear evidence that gross margins can stabilize near the low-70s and that operating expenses remain disciplined would reinforce the forecasted double-digit EPS growth and underpin a constructive reaction.
The second swing factor is the cadence of pipeline and lifecycle updates. The positive phase 3 outcome for the subcutaneous Tepezza on-body injector is a tangible catalyst that can shape medium-term expectations for the thyroid eye disease franchise. Any updates around expanding oncology programs or combination trials can further bolster conviction that the company’s product diversification will support growth beyond the current quarter. Conversely, the timing of regulatory milestones and competitive readouts could introduce volatility if expectations are mismatched with management’s timelines.
A third swing factor is external sentiment, which has been skewing supportive among major institutions entering this print. Several high-profile analysts remain constructive on out-year growth diversification, citing continued momentum in key brands and the emerging pipeline. The balance between that optimism and lingering concerns about near-term amortization drag and price negotiations will likely dictate whether the stock’s reaction is primarily driven by the headline numbers or by qualitative guidance around margins and brand-level growth trajectories.
Analyst Opinions
Across the polarized views captured in the recent period, approximately 75% are bullish and 25% are bearish, with a substantial number of neutral holds in the background; the dominant camp is bullish. The constructive side emphasizes the combination of steady base-business performance and identifiable catalysts in the pipeline and integrated assets. For example, RBC Capital Markets maintains an Outperform rating and recently raised its price target to 370 US dollars, highlighting that portfolio diversification continues to pay off and that key brands such as Repatha, Evenity, and Tezspire delivered 30%–50% growth last year, suggesting ongoing headroom in large markets. UBS has maintained a Buy rating while lifting its price target to 400 US dollars, reflecting confidence that both core and integrated therapies can deliver above-trend earnings expansion as operating leverage improves. Piper Sandler reiterated a Buy with a 432 US dollars price target, underscoring the quality of the growth portfolio and the potential for pipeline assets—alongside the established base—to support durable revenue and EPS compounding.
This supportive stance focuses on three near-term checks. First, whether the forecasted 6.60% revenue growth can be met while maintaining high-60s to low-70s gross margins despite integration amortization and profit-sharing. Second, whether adjusted EPS growth of 10.79% for the quarter is repeatable given the EBIT forecast of 3.63 billion US dollars and the mix of higher-growth brands that typically carry stronger contribution margins. Third, whether pipeline updates such as the positive phase 3 result for the subcutaneous Tepezza on-body injector translate into a clearer timeline for label or formulation expansion that could accelerate adoption in thyroid eye disease and reduce treatment friction.
The bullish view also notes that management’s capital allocation and prior-year cash flow generation have supported both debt reduction and dividends, enabling investment in growth while preserving balance-sheet flexibility. Against that backdrop, upside scenarios this quarter include: better-than-expected volume in high-growth brands lifting revenue beyond the 8.59 billion US dollars estimate; sustained gross margin resilience as mix tilts toward selected franchises; and constructive guidance on integrated assets that brightens the second-half trajectory. Even if headline revenue lands close to consensus, a firm margin outlook and tangible progress updates on late-stage or lifecycle programs would likely validate the constructive case and support multiple stability.
The minority bearish voice stresses near-term growth constraints and patent or pricing headwinds, but these concerns are, for now, outweighed by the evidence of diversified growth drivers and recent late-stage clinical wins. The prevailing perspective among institutions is that Amgen’s mix of established brands with strong momentum and visible pipeline catalysts provides a reasonable path to deliver the mid-single-digit revenue growth and double-digit EPS growth embedded in this quarter’s estimates. As a result, the majority analysis leans positive into April 30, 2026 Post Market, with attention trained on margin color, brand-level disclosures, and any updates that refine the timeline and commercial impact of pipeline and lifecycle catalysts.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments